Thermo Fisher Scientific, the world leader serving science, announced the latest recipients of the Oncomine Clinical Research Grant, designed to support emerging research on molecular profiling in oncology and to help democratize the future of precision medicine.
Now in its fourth year, the grant recognizes research from Tata Memorial Centre in India; Leiden University Center in The Netherlands; Western University in Canada; and Fred Hutch Cancer Center in the U.S.
Since its introduction in 2020, the Oncomine Clinical Research Grant program has awarded reagents and general funding for 26 unique research projects conducted by independent clinical research teams. This research spans across 16 countries and five continents, encompassing research in solid-tumors, pediatric oncology, hemato-oncology, immune-oncology and liquid biopsy, all of which help enhance the understanding of potential new applications for accessible and rapid next-generation sequencing (NGS).
“This year, we saw the highest number of Oncomine Clinical Research Grant submissions since the program began in 2020. It’s a clear indication of the industry-wide push to accelerate research that explores the impacts of genomic discovery,” said Jose Luis Costa, Ph.D., global director, scientific affairs, clinical next-generation sequencing and oncology, Thermo Fisher Scientific. "As we continue to be inspired by the achievements and discoveries of the previous awardees, doubling down on supporting the next generation of clinical researchers who will further contribute to democratizing access to NGS technology is our key priority."
For more information, please visit www.thermofisher.com.
